From Our Partners
Saturday, June 25, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

NY Blood Center Receives Funding to Develop MERS Vaccine

by Global Biodefense Staff
January 22, 2014

NYBC’s Laboratory of Viral Immunology at its Lindsley F. Kimball Research Institute has received a significant grant to continue development of a vaccine against Middle East Respiratory Syndrome coronavirus (MERS-CoV) – one of the most dangerous emerging viruses.  Lanying Du., Ph.D., Co-head of the laboratory, was awarded more than $400,000 for this program.

MERS-CoV is a novel coronavirus causing outbreaks of severe acute respiratory syndrome (SARS)-like illness in the Middle East andEurope. As of January 3, 2014, the World Health Organization had been informed of a total of 177 laboratory-confirmed cases of infection with MERS-CoV, including 74 deaths.  Because of its human-to-human transmissibility and high mortality rate (42%), MERS-CoV was called “a threat to the entire world” by Dr. Margaret Chan, the Director-General of WHO at the 66th World Health Assembly in Geneva.  The Obama administration designated MERS-CoV a threat to public health and national security, and authorized the fast-tracking of approvals of tests and treatments for MERS-CoV.

Based on NYBC’s previous experience in developing SARS vaccines, the Laboratory of Viral Immunology identified the receptor-binding domain and major neutralizing epitope that can be used for developing an anti-MERS vaccine.  The NIH grant will support further development of this vaccine candidate for prevention of MERS-CoV infection and halting the spread of this deadly virus.  InAugust 2013, Nature Medicine identified NYBC as among the pioneers in MERS-CoV vaccine research.

Source: New York Blood Center

From Our Partners
Tags: AwardsCoronavirusMERS-CoVVaccines

Related Posts

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
BARDA and JPEO-CBRND Back Cepheid’s Multiplex Test for Influenza, SARS-CoV2 and RSV
Health Security

Resurgent COVID-19, Flu and Other Viruses are Pushing New Zealand’s Health System to the Limit

June 2, 2022
NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Pathogens

How a COVID-19 Infection Spurs Antibodies Against Common Colds

May 8, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC